---
title: "Psilocybin (COMP360): Treatment-resistant depression"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression. Clinical evidence covers COMP005, COMP006, COMP001, COMP004, COMP003, PsiDeR, and 1 further heading. 797 evidence topics quoted from 261 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360): Treatment-resistant depression

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Psilocybin

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Treatment-resistant depression

<a id="topic-1.1.1-1"></a>

##### Summary: definition and epidemiology

A consensus definition of TRD with demonstrated predictive utility does not currently exist. The FDA and EMA use inadequate response to a minimum of two antidepressants despite an adequate treatment trial and adherence, and ICER's draft scope population is adults with MDD for whom “two or more prior antidepressants prescribed at adequate dose and duration, during the current episode, have not resulted in adequate therapeutic benefit”. In the United States, a synthesis of 4 claims studies (Medicare, Medicaid, commercial plans, and the Veterans Health Administration) estimated 8.9 million adults with medication-treated MDD over 12 months, of whom 2.8 million (30.9%) had TRD; ICER cites the same 2.8 million. In 2025, 19.7 million adults aged 18 or older (7.4%) had a past-year major depressive episode, and 10.2 million of them (51.7%) took prescription medication for their mental health. In two cohorts, 10.4% of 230,801 people newly diagnosed and treated for depression developed TRD within 1 year, and 9.6% of 355,942 people with MDD met TRD criteria. Estimates depend on the definition: claims-based incidence varied 6-fold or 7-fold within a database across implementation choices, and real-world prevalence is estimated to range between 6 and 55%. In a cohort of 158 169 unipolar MDD episodes, 11% met TRD criteria.

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/); [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf); [Zhdanava et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33989464/); [SAMHSA (2026)](https://www.samhsa.gov/data/sites/default/files/reports/rpt57150/2025-nsduh-annual-national-html/2025-nsduh-annual-national.htm); [Cepeda et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6055726/); [Li et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6771113/); [Fife et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6076365/); [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-1.1.1-2"></a>

##### Summary: natural history and mortality

QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% at the first to fourth acute treatment steps, and participants who required more steps had higher relapse rates during follow-up. A review of 9 outcome studies (1279 participants) found that as many as 80% of those requiring multiple treatments relapsed within a year of remission and that the probability of recovery within 10 years was about 40%. Under treatment as usual, 24-month response and remission rates were 18.4% (19/103) and 7.8% (8/103). In one cohort, TRD was associated with higher all-cause mortality than non-TRD MDD (adjusted HR 1.29; 95% CI 1.22–1.38). In a cohort of 139,753 people with TRD, suicide mortality was 0.14/100 person-years with TRD and 0.04/100 person-years with MDD alone, and ICER's draft scope states a “greater than 3-fold risk of death by suicide” than with non-TRD MDD. Another cohort reported an adjusted all-cause mortality HR of 1.35 (95% CI 1.21-1.50) and an external-cause mortality HR of 1.97. Another study reported an overall incidence of 0.47 completed and 4.66 attempted suicides per 100 patient years in TRD.

Source: [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/); [Fekadu et al. (2009a)](https://pubmed.ncbi.nlm.nih.gov/19007996/); [Dunner et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16841617/); [Li et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6771113/); [Kern et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10454258/); [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf); [Reutfors et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29966932/); [Bergfeld et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29665520/)

<a id="topic-1.1.1-3"></a>

##### Summary: humanistic burden and long-term morbidity

In a study of 2467 participants (377 with TRD and 2090 without), those with TRD had lower SF-12 mental component scores (30 vs 45.7) and Q-LES-Q scores (43.6 vs 63.7), and WPAI overall work impairment of 52.9% versus 24.9%. A review of 62 articles found quality-of-life scores “.41±.8 and .26±.8 points lower” in TRD than in remission or response, respectively. In a cohort of 411 participants in seven European countries, mean EQ-5D-5L score at baseline was 0.41 and 30.2% were unemployed. ICER's 2019 esketamine model used utilities of 0.86 for no depression, 0.68 for mild to moderate depression, and 0.50 for severe depression. TRD is a risk factor for incident cardiovascular disease, type 2 diabetes mellitus, osteoporosis, and metabolic syndrome. In a cohort of 23,335 people with TRD, the hazard of cardiovascular death was higher (aHR 1.32) without additional overall risk of major adverse cardiovascular events. Compared with matched non-TRD episodes, TRD episodes had 132.3 versus 58.7 mean lost workdays in the 12 months after the index date.

Source: [DiBernardo et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6206859/); [Mrazek et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24789696/); [Heerlein et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33545659/); [ICER final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf); [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/); [Nygren et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40381860/); [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-1.1.1-4"></a>

##### Summary: economic burden and healthcare resource utilization

In the United States, the total annual burden of medication-treated MDD was estimated at $92.7 billion, of which $43.8 billion (47.2%) was attributable to TRD, including $25.8 billion of the health care burden. Four cohort studies report higher per patient per year health care costs with TRD than with non-TRD MDD: $6,709, an adjusted $3,377 (unadjusted totals $25,059 vs $19,945), US$4382, and $5,906 more. Participants with TRD who had work loss data (N = 1,908) had 35.8 work loss days per patient per year and $1,811 higher work loss costs than those with non-TRD MDD. In the study reporting the adjusted $3,377 difference, the TRD cohort had a higher rate of behavioral health-related inpatient visits than the non-TRD MDD cohort (IRR 1.49). A review of 62 articles found annual health care and lost productivity costs $5,481 and $4,048 higher, respectively, than in treatment-responsive depression, and estimated an added societal cost of $29-$48 billion per year. Across 12 studies, direct and indirect costs rose with increasing levels of non-response. Compared with matched non-TRD episodes, TRD episodes had 3.9 versus 1.3 mean inpatient bed-days in the 12 months after the index date.

Source: [Zhdanava et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33989464/); [Amos et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29474009/); [Pilon et al. (2019b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6786597/); [Pilon et al. (2019a)](https://pubmed.ncbi.nlm.nih.gov/30734581/); [Szukis et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33879005/); [Mrazek et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24789696/); [Johnston et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30195173/); [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-1.1.1-5"></a>

##### Summary: burden on caregivers and families

Across all adults with MDD in the United States in 2019, an estimated 17 million household members without MDD lost $80.1 billion in annual income. In a caregiver survey (169 TRD caregivers and 1070 No TRD caregivers), TRD caregivers provided 23.3 versus 14.6 mean weekly caregiving hours. Adjusted annual indirect costs were $11,121 versus $7761, with presenteeism the largest component, and adjusted annual direct costs were $29,805 versus $20,642. More TRD caregivers reduced their work hours (29.0% vs 11.5%), took a leave of absence (11.1% vs 5.2%), had out-of-pocket caregiving expenses (45.5% vs 22.2%), and screened positive for depression (16.8% vs 6.7%). The survey was cross-sectional, used a convenience sample, and operationalized TRD by self-report with a tool not tested for reliability and validity. In a matched cohort, 2,359 first-born offspring of parents with TRD had adjusted hazard ratios of 4.6 for depression and 3.2 for suicide attempt, and their relative risks were similar to those of offspring of parents with other depression.

Source: [Greenberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499687/); [Lerner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7478216/); [Brenner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12996023/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Psilocybin Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary: COMP005 phase 3 design and Week 6 primary result

COMP005 is a phase 3, randomized, double-blind, placebo-controlled trial in which adults with TRD (2 to 4 inadequate prior treatment responses) were randomized 2:1 to a single dose of COMP360 25 mg or matched placebo, administered with psychological support. A total of 258 participants were dosed (171 COMP360, 87 placebo) at 40 sites in the United States according to the Form 10-K; the 2025 Form 8-K topline filing states 32 sites. Part A was blinded through Week 6, Part B was blinded from Week 6 to Week 26, and Part C was open-label from Week 26 to Week 52. The primary endpoint was the difference between arms in change from baseline in MADRS total score at Week 6, from a mean baseline score of 31.5 in both arms. The least squares mean difference at Week 6 was -3.6 points (95% CI -5.7 to -1.5; p<0.001). Differences at earlier visits were -4.7 at Day 2, -7.2 at Week 1, and -5.2 at Week 3 (each p<0.001). In a post hoc analysis, 25% of participants in the 25 mg arm had a MADRS reduction of at least 25% at Week 6. These results come from Form 8-K filings, the Form 10-K, a November 2026 investor presentation that describes them as preliminary, and Psych Congress Elevate congress abstracts.

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268); [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm); [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm); [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)

<a id="topic-1.1.2-2"></a>

##### Summary: COMP005 Part B and Part C through Week 52

In Part B, participants who did not remit by Week 6 or who later met relapse criteria could receive a second dose of their randomized treatment; 70% of the COMP360 arm and 53% of the placebo arm received a second administration. The congress abstract states that “numerical separation from placebo was maintained through Week 26”. No statistical analyses were performed after the Week 6 primary analysis, and Part B results are based on observed data only. The company reports that over 40% of participants who had a clinically meaningful MADRS reduction but had not remitted by Week 6 remitted after the second dose. Approximately 70% of participants entered open-label Part C, where 90 participants from the 25 mg arm (approximately 80% of those entering) and 52 from the original placebo arm (approximately 90%) received a 25 mg dose. The company reports an average 13-point MADRS reduction from baseline at Week 52 in the 25 mg arm and an average 10-point reduction at the end of Part C in the original placebo arm, with response rates of 40% to 45% and remission rates of approximately 30% between Day 1 and Week 6 after the Part C dose, based on the 142 participants dosed in Part C. These results come from company documents and a congress abstract.

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm); [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

<a id="topic-1.1.2-3"></a>

##### Summary: COMP006 phase 3 design and Part A results at Weeks 6 and 9

COMP006 is a phase 3, randomized, double-blind trial in which adults with TRD were randomized 2:1:1 to two doses, 3 weeks apart, of COMP360 25 mg, 10 mg, or 1 mg. The company reports 581 dosed participants (296, 142, and 143) at 116 sites in the United States, Canada, and Europe; the registry lists actual enrollment of 572. Part A was blinded through Week 9, Part B through Week 26, and Part C is an open-label part from Week 26 to Week 52. The primary endpoint was the difference in change from baseline in MADRS total score between the 25 mg and 1 mg groups at Week 6, and Week 9 was a key secondary endpoint. At Week 6, the least squares mean difference was -3.8 points for 25 mg versus 1 mg (95% CI -5.8 to -1.8; p<0.001) and -2.5 for 10 mg versus 1 mg (95% CI -4.9 to -0.2; p=0.016), which the November 2026 presentation reports as -2.5 (-4.8, -0.2) with a p-value of 0.017. At Week 9, the differences were -2.9 (p=0.002) and -2.6 (p=0.016). In a post hoc analysis, 39% of the 25 mg arm had a MADRS reduction of at least 25% at Week 6. These results come from Form 8-K filings, company presentations, and a congress abstract.

Source: [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm); [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940); [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-1.1.2-4"></a>

##### Summary: COMP006 Part B through Week 26

In Part B, participants meeting prespecified criteria could receive retreatment with their randomized dose or an antidepressant, and protocol-allowed antidepressants were permitted in Parts B and C; up to 4 doses of COMP360 are possible across 52 weeks. In the 25 mg arm, 58% of participants received retreatment after Week 9. The company reports “consistent separation between the 25 mg and the 1 mg arm” through Week 26, and Part B results after Week 9 are observed data only. The 39% of the 25 mg arm with a clinically meaningful MADRS reduction at Week 6 maintained benefit, on average, through at least Week 26, and 28% of participants with a clinically meaningful reduction who had not remitted by Week 6 remitted after an additional dose in Part B. Participants had current depressive episodes lasting on average over three years and an average of more than six lifetime depressive episodes. The registry lists study completion as estimated for 2026-12 and shows no results posted. These results come from a Form 8-K filing and a company investor presentation.

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm); [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-1.1.2-5"></a>

##### Summary: phase 2b COMP001 and the COMP004 follow-up

COMP001 was a phase 2b, randomized, double-blind trial in which 233 adults with TRD received a single dose of COMP360 25 mg (n=79), 10 mg (n=75), or 1 mg (n=79) with psychological support at 22 sites in 10 countries. The mean baseline MADRS total score was 32 or 33 in each group. In the peer-reviewed publication, least squares mean changes from baseline to Week 3 were -12.0, -7.9, and -5.4; the difference was -6.6 for 25 mg versus 1 mg (95% CI -10.2 to -2.9; P<0.001) and -2.5 for 10 mg versus 1 mg (95% CI -6.2 to 1.2; P = 0.18). The authors state that in the 25 mg group, response and remission at Week 3, “but not sustained response at 12 weeks,” were generally supportive of the primary results. The company reports remission in 29.1% of the 25 mg group at Week 3 and sustained response at Week 12 in 20.3% versus 10.1% with 1 mg. COMP004, a peer-reviewed 52-week observational follow-up of 66 participants (58 from COMP001), reported median time to a depressive event for all 233 COMP001 participants of 92 days for 25 mg, 83 days for 10 mg (86 days in the Form 10-K), and 62 days for 1 mg; a post hoc analysis of enrolled participants gave 189, 43, and 21 days, based on 10 events after enrollment.

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [COMPASS Pathways NEJM publication release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx); [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-1.1.2-6"></a>

##### Summary: supporting studies COMP003, PsiDeR, and the phase 1 study

COMP003 was a phase 2, exploratory, open-label study without a comparator in which 19 participants with TRD received a single 25 mg dose while continuing a single SSRI. In its peer-reviewed report, the mean MADRS change from baseline at Week 3 was -14.9 (95% CI -20.7 to -9.2), and 42.1% of participants met response and remission criteria at Week 3. PsiDeR was a single-site, double-blind, placebo-controlled phase 2 feasibility trial sponsored by the South London and Maudsley NHS Foundation Trust and King’s College London, in which 60 participants were randomized 1:1 to COMP360 25 mg or placebo after withdrawal of antidepressants; COMPASS Pathfinder supplied the capsules and had no role in design, conduct, or analysis. The adjusted MADRS difference was -10.41 at Week 3 and -12.92 at Week 6, and at Week 3, 13 (43%) psilocybin versus 1 (3%) placebo participants met response criteria and 12 (40%) versus 1 (3%) met remission criteria. The COMPASS-sponsored phase 1 study (EudraCT 2018-000978-30) randomized 89 healthy participants to 25 mg, 10 mg, or placebo, given simultaneously to up to six participants, and found no clinically relevant between-group differences in CANTAB or emotional processing scores. All three studies are reported in peer-reviewed publications.

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/); [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/); [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-1.1.2-7"></a>

##### Summary: safety in the phase 3 trials

In COMP005, any treatment-emergent adverse event (TEAE) occurred in 120 (70.2%) COMP360 and 34 (39.1%) placebo participants through Week 6, and in 145 (84.8%) and 52 (59.8%) through Week 26. Headache, nausea, and visual hallucination were the most common TEAEs; 66% of TEAEs occurred on dosing days and 88% resolved within a day. Serious TEAEs through Week 26 occurred in 8 (4.7%) COMP360 and 2 (2.3%) placebo participants, including suicidal ideation in 4 (2.3%) COMP360 participants. In COMP006 Part A, any TEAE through Week 9 occurred in 274 (92.6%), 125 (88.0%), and 116 (81.1%) participants in the 25 mg, 10 mg, and 1 mg arms; 73% of TEAEs occurred on dosing days and 83% resolved within a day. Nausea (39.9% versus 10.5%) and blood pressure increased (10.5% versus 2.8%) occurred more often with 25 mg than with 1 mg. Through Week 26, serious TEAEs occurred in 17 (5.7%), 5 (3.5%), and 9 (6.3%) participants, with suicidal ideation in 4 (1.4%), 2 (1.4%), and 4 (2.8%), one suspected suicide in the 25 mg arm determined by the investigator as “not related to the treatment”, and one suicide attempt in the 1 mg arm. The data safety monitoring board found no evidence of a clinically meaningful imbalance in suicidality between arms in either trial. These data come from company filings and presentations.

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

<a id="topic-1.1.2-8"></a>

##### Summary: safety in the phase 2 and supporting studies

In COMP001, adverse events occurred in 179 of 233 participants (77%), including headache, nausea, and dizziness, and suicidal ideation or behavior or self-injury occurred in all dose groups. Serious adverse events occurred in 5/79 (6.33%), 6/75 (8.00%), and 1/79 (1.27%) participants in the 25 mg, 10 mg, and 1 mg groups, including suicidal behaviour in 3/79 (3.80%) with 25 mg; the company states that these behaviours were reported at least one month after dosing in three non-responders. In COMP003, 12 of 19 participants (63.2%) had a TEAE and none was serious; three participants had blood pressure increased, of whom two had severe events treated with clonidine. In PsiDeR, four serious adverse events were recorded (one placebo, three psilocybin), all but one deemed not related to study medication, with the remaining event, in the placebo arm, deemed possibly related. In the phase 1 study in healthy participants, there were no serious TEAEs, 67% of adverse events started and resolved on the administration day, one participant had substance-induced psychotic disorder and received midazolam, and there were no clinically significant findings in vital signs. The COMP001 figures come from the peer-reviewed publication and the registry, except the timing of suicidal behaviour, which comes from a company press release; the other three studies are reported in peer-reviewed publications.

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/); [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results); [COMPASS Pathways NEJM publication release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx); [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/); [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/); [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Psilocybin

<a id="topic-1.1.3-1"></a>

##### Summary: price, reimbursement pathway, and coding

No price or wholesale acquisition cost for COMP360 is quoted in any source in this report. On its third quarter 2026 earnings call, the company said pricing depends on “the value that these products are bringing to the healthcare system”, and a news report states that Nath said Spravato “provides a reference point but declined to commit to a specific pricing benchmark.” The company's November 2026 investor presentation states that COMP360 is “expected to be available through specialty pharmacy and buy-and-bill”, with the “drug reimbursed through pharmacy benefit” and session monitoring “billed by the hour through medical benefit” under CPT Category III codes for psychedelic drug monitoring, “effective on January 1, 2024”. The same presentation states that “Coding and reimbursement for COMP360 have not yet been established and are subject to change from current thinking”. On the earnings call, discussing coding and reimbursement, the company said “we anticipate that taking 12-18 months” and that sites would receive coding support and patients would have support programs in the interim. The company's 2026 Form 10-K states that, while psilocybin is in Schedule I, therapies that use it “are currently precluded from reimbursement in the United States.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/); [Keshavan (2026)](https://www.statnews.com/2026/10/14/compass-pathways-psychedelics-stat-summit/); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-1.1.3-2"></a>

##### Summary: regulatory and scheduling preconditions for launch

The company announced that it “completed its submission of a New Drug Application (NDA)” for COMP360 in treatment-resistant depression. The Commissioner's National Priority Voucher awarded in April 2026 carries a review target of 1 to 2 months after filing. The company anticipates launch “in the first half of 2027 subject to FDA approval and following Drug Enforcement Administration, or DEA, rescheduling.” Its Form 10-K states that psilocybin and psilocin must be rescheduled, or the product scheduled, “to Schedule II, III, IV or V” before commercial marketing, and that “most state laws in the U.S. classify psilocybin and psilocin as Schedule I controlled substances.” On the earnings call the company described the DEA's “90-day statutory timeline” for rescheduling, which it said the White House executive order of 2026 seeks to expedite, and said “over 93% of the U.S. population” lives in states that have stated an intent to reschedule within 30 days after federal action. Prescribing, distribution, and reimbursement of COMP360 therefore follow FDA approval and federal and state rescheduling.

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx); [COMPASS Pathways rolling review and voucher release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Granted-NDA-Rolling-Review-Request-and-Awarded-Commissioners-National-Priority-Voucher/default.aspx); [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm); [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/); [White House (2026)](https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/)

<a id="topic-1.1.3-3"></a>

##### Summary: ICER assessment of synthetic psilocybin

The Institute for Clinical and Economic Review (ICER) will assess “the comparative clinical effectiveness and value of synthetic psilocybin (COMPASS Pathways) for treatment-resistant depression.” The draft scope names “Psilocybin (25 mg)” as the intervention and esketamine or intravenous ketamine and repetitive transcranial magnetic stimulation as comparators, in adults with major depressive disorder without psychotic features after two or more adequate antidepressant trials in the current episode. The cost-effectiveness model will take a health care system perspective with a five-year base-case horizon, “reflecting uncertainty in the durability of treatment effects”, estimate effectiveness by network meta-analysis, and report cost per QALY, evLY, life-year, and case of remission gained. A separate budget impact analysis over five years will use published or publicly available estimates of the eligible population; the draft scope cites “an estimated 2.8 million” Americans with TRD among those treated for MDD. ICER's schedule lists the revised scoping document on 11/18/2026, the model analysis plan on 01/22/2027, the draft evidence report on 03/16/2027, and the final evidence report and meeting summary on 06/21/2027.

Source: [ICER (2026)](https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-to-assess-therapy-for-treatment-resistant-depression/); [ICER TRD assessment page (2026)](https://icer.org/assessment/treatment-resistant-depression-2027/); [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-1.1.3-4"></a>

##### Summary: published cost-effectiveness analyses of psilocybin therapy

Three peer-reviewed analyses model psilocybin therapy in depression; none states a price for COMP360.

- 12 months, limited healthcare perspective: with an assumed total therapy cost of $5000 (varied from $3000 to $20,000), psilocybin-assisted therapy added 0.031 QALYs and $3639 in costs compared with standard of care, an incremental ratio of $117,517 per QALY gained, with a 75% probability of cost-effectiveness at $150,000 per QALY. That probability was 1% at a total cost of $10,000 and 95% at $3000.
- PubMed abstract: compared with standard of care, therapy was “more effective and less costly”, with approximately $7000 in savings and 0.10 QALYs gained per patient; a 30-year horizon gave savings of $215 900 and 9.87 QALYs.
- Costs in pounds sterling: expected healthcare cost of therapy was £6132 to £7652 depending on the psilocybin price, with 0.310 QALYs for psilocybin against 0.278 to 0.287 for the alternatives. Psilocybin was cost-effective when therapist support cost fell by 50% and the drug price fell to £400 to £800 per person.

Source: [Avanceña et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397412/); [Ziadi and Park (2026)](https://pubmed.ncbi.nlm.nih.gov/41842876/); [McCrone et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755218/)

<a id="topic-1.1.3-5"></a>

##### Summary: comparator costs and utilization

- Esketamine, ICER 2019: at a WAC of “$295 per 28 mg device”, an annual average WAC of $32,400, ICER estimated approximately $198,000 per QALY gained and $2.6 million per life-year gained. Annual prices of $17,700 and $25,200 would meet thresholds of $100,000 and $150,000 per QALY, a discount from WAC of “25-52%”.
- Esketamine, published analysis: base-case ratios were $237,111 per QALY (societal) and $242,496 per QALY (healthcare sector), and the value-based price at $150,000 per QALY was approximately $140 per dose against a current price of $240 per dose.
- Cohorts initiating esketamine (151), electroconvulsive therapy (198), or transcranial magnetic stimulation (140): mean mental health-related inpatient costs were $76, $1,547, and $238, and outpatient costs were $1,632, $1,023, and $1,051; the authors state the comparison “should be interpreted with caution”.
- Utilization: the company states that fewer than 3% of an estimated 4 million people in the United States with TRD are treated with Spravato.

Source: [ICER final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf); [Ross and Soeteman (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7920520/); [Clemens et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/43010363/); [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-1.1.3-6"></a>

##### Summary: delivery-model cost drivers

- Session length: a COMP360 administration session “lasts approximately six to eight hours”, which the company contrasts with the “six hours versus two hours requirement” for Spravato.
- Monitoring staff: the company's trial design used “one primary monitor” with closed-circuit television, “two total healthcare providers” in all, and it anticipates REMS requirements “no more stringent” than in the trials. Group monitoring saved 34.7% of clinician costs, or $981 per patient, for psilocybin in major depressive disorder in one published analysis.
- REMS: the company expects a REMS, states that the FDA directed it to use the Spravato REMS as a template, and states in its Form 10-K that REMS programs “are costly and time-consuming for providers to comply with”. REMS training content is expected to take “about one to two hours to review.”
- Treatment-center capacity: the company cites “more than 8,500 interventional psychiatry treatment centers” in the United States.
- Payer views: a payer panel raised concern about the cost-effectiveness of “potentially requiring multiple health professionals at specialized centers”.

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/); [Marseille et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10731307/); [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

COMPASS Pathways completed its NDA for COMP360 in TRD on November 9, 2026, and its Commissioner's National Priority Voucher “could shorten review times to 1-2 months”. Psilocybin is in Schedule I; launch is anticipated in the first half of 2027, subject to FDA approval and DEA rescheduling. TRD affected 2.8 million (30.9%) of 8.9 million US adults with medication-treated MDD and accounted for $43.8 billion in annual burden.

In COMP005 (258 participants), one 25 mg dose reduced MADRS score more than placebo at Week 6 (difference -3.6; p<0.001). In COMP006 (581 participants), two 25 mg doses reduced it more than two 1 mg doses (-3.8; p<0.001). Observed or open-label durability data show an average 13-point reduction at Week 52 in the COMP005 25 mg arm after another dose, and benefit maintained through at least Week 26 by the 39% of the COMP006 25 mg arm with a clinically meaningful Week 6 reduction. Phase 3 results come from company filings, presentations, and congress abstracts. In the peer-reviewed phase 2b COMP001 trial (233 participants), the Week 3 difference for 25 mg versus 1 mg was -6.6 (P<0.001); response and remission at Week 3 were supportive of the primary result, and sustained response at 12 weeks was not.

Headache, nausea, and visual hallucination were common, primarily on dosing days. Serious TEAEs through Week 26 of COMP005 occurred in 4.7% (COMP360) and 2.3% (placebo), and the data safety monitoring board found no clinically meaningful suicidality imbalance in either trial.

Sessions last six to eight hours at a certified treatment center, with two monitoring healthcare providers in the trials and an expected REMS templated on the Spravato REMS.

No price is published. ICER's final evidence report is scheduled for 06/21/2027; published psilocybin analyses report $117,517 per QALY gained or cost savings.

Limitations are functional unblinding, no active comparator, preliminary phase 3 data with no COMP006 registry results, and discrepancies between company sources (40 or 32 COMP005 sites; 581 dosed or 572 enrolled in COMP006).

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx); [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm); [Zhdanava et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33989464/); [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm); [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/); [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888); [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm); [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/); [ICER TRD assessment page (2026)](https://icer.org/assessment/treatment-resistant-depression-2027/); [Avanceña et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397412/); [Ziadi and Park (2026)](https://pubmed.ncbi.nlm.nih.gov/41842876/); [Goodwin et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36740140/); [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm); [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

## Related pages
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
